Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CME Group ( (CME) ).
On July 25, 2025, a jury ruled in favor of CME Group Inc. and the Board of Trade of the City of Chicago, Inc. in a class action lawsuit. The plaintiffs, Class B shareholders and members, alleged breaches of contract and good faith, but the verdict supported the defendants, potentially reinforcing their legal standing and shareholder relations.
The most recent analyst rating on (CME) stock is a Sell with a $191.00 price target. To see the full list of analyst forecasts on CME Group stock, see the CME Stock Forecast page.
Spark’s Take on CME Stock
According to Spark, TipRanks’ AI Analyst, CME is a Outperform.
CME Group’s overall stock score is driven by its robust financial performance and positive earnings call sentiment, marked by record volumes and international growth. Valuation metrics and technical analysis provide additional support, while macroeconomic uncertainties pose challenges.
To see Spark’s full report on CME stock, click here.
More about CME Group
CME Group Inc. operates in the financial services industry, primarily offering a range of derivatives and futures products. The company is a major player in global financial markets, facilitating trading across various asset classes.
Average Trading Volume: 2,341,207
Technical Sentiment Signal: Buy
Current Market Cap: $99.88B
For detailed information about CME stock, go to TipRanks’ Stock Analysis page.